tbuckley/cabot-search huggingface dataset:
Lepodisiran — A Long-Duration Small Interfering RNA Targeting Lipoprotein(a)
Authors: Steven E Nissen, Wei Ni, Xi Shen, Qiuqing Wang, Ann Marie Navar, Stephen J Nicholls, Kathy Wolski, Laura Michael, Axel Haupt, John H Krege
Journal: New England Journal of Medicine (2025)

BackgroundElevated lipoprotein(a) concentrations are associated with atherosclerotic cardiovascular disease. The safety and efficacy of lepodisiran, an extended-duration, small interfering RNA targeting hepatic synthesis of lipoprotein(a), are unknown.MethodsWe randomly assigned participants in a 1:2:2:2:2 ratio to receive lepodisiran at a dose of 16 mg, 96 mg, or 400 mg at baseline and again at day 180, lepodisiran at a dose of 400 mg at baseline and placebo at day 180, or placebo at baseline and at day 180, all administered by subcutaneous injection. Data from the two groups that received lepodisiran at a dose of 400 mg at baseline were pooled for the primary analysis. The primary end point was the time-averaged percent change from baseline in the serum lipoprotein(a) concentration (lepodisiran difference from placebo [i.e., placebo-adjusted]) during the period from day 60 to day 180.ResultsA total of 320 participants underwent randomization; the median baseline lipoprotein(a) concentration was 253.9 nmol per liter. The placebo-adjusted time-averaged percent change from baseline in the serum lipoprotein(a) concentration from day 60 to day 180 was −40.8 percentage points (95% confidence interval [CI], −55.8 to −20.6) in the 16-mg lepodisiran group, −75.2 percentage points (95% CI, −80.4 to −68.5) in the 96-mg group, and −93.9 percentage points (95% CI, −95.1 to −92.5) in the pooled 400-mg groups. The corresponding change from day 30 to day 360 was −41.2 percentage points (95% CI, −55.4 to −22.4), −77.2 percentage points (95% CI, −81.8 to −71.5), −88.5 percentage points (95% CI, −90.8 to −85.6), and −94.8 percentage points (95% CI, −95.9 to −93.4) in the 16-mg, 96-mg, 400-mg–placebo, and 400-mg–400-mg dose groups, respectively. Serious adverse events, none of which were deemed by investigators to be related to lepodisiran or placebo, occurred in 35 participants. Dose-dependent, generally mild injection-site reactions occurred in up to 12% (8 of 69) of the participants in the highest lepodisiran dose group.ConclusionsLepodisiran reduced mean serum concentrations of lipoprotein(a) from 60 to 180 days after administration. (Funded by Eli Lilly; ALPACA ClinicalTrials.gov number, NCT05565742.)
A RARE COMPLICATION OF INFECTIVE ENDOCARDITIS: LEFT VENTRICULAR PSEUDOANEURYSM MASQUERADING AS SEVERE MITRAL REGURGITATION
Authors: Mohamed Allam, Girish Pathangey, Christopher N. Kanaan, Ramzi Ibrahim, Mahmoud Abdelnabi, Ahmed K. Mahmoud, Kristen Sell-Dottin, Said Alsidawi
Journal: Journal of the American College of Cardiology (2025)
ASSOCIATIONS BETWEEN POLYGENIC RISK SCORE AND INFLAMMATION-RELATED GENETIC VARIANTS WITH CARDIOVASCULAR OUTCOMES IN INDIVIDUALS WITH HIV: INSIGHTS FROM THE REPRIEVE TRIAL
Authors: Roger Zou, Yunfeng Ruan, Buu Truong, Romit Bhattacharya, Michael T. Lu, Julia Karady, Rachel Bernardo, Phoebe Finneran, Whitney Hornsby, Kathleen Fitch, Heather Jane Ribaudo, Markella Zanni, Pamela S. Douglas, Steven Grinspoon, Aniruddh Patel, Pradeep Natarajan
Journal: Journal of the American College of Cardiology (2025)
REGULAR ASPIRIN USE, LIPOPROTEIN(A), LDL-CHOLESTEROL AND INCIDENT AORTIC VALVE CALCIUM: THE MULTI-ETHNIC STUDY OF ATHEROSCLEROSIS
Authors: Alexander C. Razavi, Harpreet Bhatia, Natalie Marrero, Omar Dzaye, Wendy S. Post, Khurram Nasir, Michael Tsai, Viola Vaccarino, Vasan S. Ramachandran, George Thanassoulis, Sotirios Tsimikas, Laurence S. Sperling, Matthew J. Budoff, Roger S. Blumenthal, Michael J. Blaha, Seamus P. Whelton
Journal: Journal of the American College of Cardiology (2025)
BUILDING ECHOGPT: A LARGE LANGUAGE MODEL FOR ECHOCARDIOGRAPHY REPORT SUMMARIZATION
Authors: Chieh Ju Chao, Imon Banerjee, Reza Arsanjani, Chadi Ayoub, Andrew S. Tseng, Garvan C. Kane, Jae K. Oh, Fei-Fei Li, Ehsan Adeli, Curtis P. Langlotz
Journal: Journal of the American College of Cardiology (2025)
EARLY DETECTION OF TRANSTHYRETIN AMYLOID CARDIOMYOPATHY THROUGH CARPAL TUNNEL DECOMPRESSION BIOPSIES -A PROSPECTIVE MULTICENTRE UNITED KINGDOM STUDY
Authors: Yousuf Razvi, Adam Ioannou, Aldostefano Porcari, Helen J. Lachmann, Ashutosh Wechalekar, Carol Jane Whelan, Lucia Venneri, Marianna Fontana, Julian D. Gillmore
Journal: Journal of the American College of Cardiology (2025)
CONTRIBUTIONS OF SOCIAL DETERMINANTS OF HEALTH TO RACIAL AND ETHNIC DIFFERENCES IN AGE OF ONSET OF HEART FAILURE
Authors: Xiaoning Huang, Lucia Petito, Gregg C. Fonarow, Faraz S. Ahmad, Nilay S. Shah, Sarah Chuzi, Kiarri Kershaw, Philip Greenland, Sadiya Sana Khan
Journal: Journal of the American College of Cardiology (2025)
EXERCISE CARDIAC MAGNETIC RESONANCE MYOCARDIAL DYNAMIC INDEX: A NON-INVASIVE IMAGING MARKER OF VO2 MAX
Authors: Fahime Ghanbari, Jennifer Rodriguez, Connie W. Tsao, Jeremy Robbins, Deepa Mangalat Gopal, David Systrom, Aaron B. Waxman, Warren J. Manning, Reza Nezafat
Journal: Journal of the American College of Cardiology (2025)
PROTEOMICS PROFILING REVEALS DISTINCT MOLECULAR SUBTYPES OF TRANSTHYRETIN CARDIAC AMYLOIDOSIS
Authors: Itsuki Osawa, Keitaro Akita, Sergio Luis Teruya, Dimitrios Bampatsias, Alfonsina Mirabal, Mathew S. Maurer, Yuichi J. Shimada
Journal: Journal of the American College of Cardiology (2025)
SPLENIC FOLLICULAR B CELLS PROMOTE ADVERSE CARDIAC REMODELING AFTER MYOCARDIAL INFARCTION VIA MHC II-DEPENDENT ANTIGEN PRESENTATION
Authors: Jana Lovell, Carolina Duque, Obialunanma Ebenebe, Yiran Song, Sylvie Rousseau, Aashik Bhalodia, Kevin C. Bermea, Charles Cohen, Luigi Adamo
Journal: Journal of the American College of Cardiology (2025)
COMPARISON OF RADIOTHERAPY FRACTIONATION SCHEMES AND ADJUVANT ANTI-HER2 THERAPIES ON CARDIOTOXICITY IN HER2-POSITIVE BREAST CANCER PATIENTS
Authors: Omar Alomari, Hüseyin Tepetam, Şule Karabulut Gül, Muhammed Edib Mokresh, Melike Pekyürek Varan, Öznur Taşlıyurt, Gökhan Yaprak, Sedat Yıldırım, Hatice Odabaş
Journal: Journal of the American College of Cardiology (2025)
ONE-YEAR OUTCOME IN THE FIRST PUBLIC CATHETERIZATION LABORATORY IN A MIDDLEINCOME COUNTRY: GUATEMALA’S AWAKENING PROCESS
Authors: Nancy Paola Vargas-San José, Mariana Gil Salazar, Alexis Miguel Monroy-Portillo, Carlos andres Sandoval santos, Sonia Margarita Moreno-Díaz, Jose Antonio Cornejo-Guerra
Journal: Journal of the American College of Cardiology (2025)
Evolutionary history of bilaterian <i>FoxP</i> genes: complex ancestral functions and evolutionary changes spanning 2R-WGD in the vertebrate lineage
Authors: Fu-Yu Tsai, Che-Yi Lin, Yi-Hsien Su, Jr-Kai Yu, Dian-Han Kuo
Journal: Molecular Biology and Evolution (2025)

Human and fly FoxP homologs are well-known for their roles in the development of cognitive abilities. These findings have led to the hypothesis that the ancestral function of FoxP was in the development of cognitive neural circuits. However, complex brains in human and fly evolved independently, and the similar cognitive function of FoxP in human and fly may thus be interpreted as a result of convergent evolution. In addition, the four gnathostome FoxP paralogs also possess diverse developmental functions unrelated to neurodevelopment, which might have been overlooked in comparative studies of invertebrate FoxP homologs. To resolve these uncertainties, we set out to improve the phylogenetic reconstruction of vertebrate FoxP homologs and broaden the taxonomic sampling of gene expression profiling to include an invertebrate chordate, ambulacrarian deuterostomes, and a spiralian protostome. Using phylogenetic analysis combined with synteny mapping, we elaborated the hypothesis that the four FoxP paralogs arose through the 2R-WGD events shared by all gnathostome species. Based on this evolutionary scenario, we examined the FoxP expression pattern in amphioxus development and concluded that FoxP already had complex developmental functions across all germ layers in the chordate ancestor. Moreover, in sea urchin, hemichordate, and catenulid flatworm, FoxP was expressed in the gut prominently, in addition to the anterior neurogenic ectoderm. This surprising similarity shared among these distantly related species implies that FoxP may have a significant function in gut development in addition to the neural development function in the last common ancestor of bilaterians.
Genotype inference from aggregated chromatin accessibility data reveals genetic regulatory mechanisms
Authors: Brandon M. Wenz, Yuan He, Nae-Chyun Chen, Joseph K. Pickrell, Jeremiah H. Li, Max F. Dudek, Taibo Li, Rebecca Keener, Benjamin F. Voight, Christopher D. Brown, Alexis Battle
Journal: Genome biology (2025)

Abstract Background Understanding the genetic causes underlying variability in chromatin accessibility can shed light on the molecular mechanisms through which genetic variants may affect complex traits. Thousands of ATAC-seq samples have been collected that hold information about chromatin accessibility across diverse cell types and contexts, but most of these are not paired with genetic information and come from distinct projects and laboratories. Results We report here joint genotyping, chromatin accessibility peak calling, and discovery of quantitative trait loci which influence chromatin accessibility (caQTLs), demonstrating the capability of performing caQTL analysis on a large scale in a diverse sample set without pre-existing genotype information. Using 10,293 profiling samples representing 1454 unique donor individuals across 653 studies from public databases, we catalog 24,159 caQTLs in total. After joint discovery analysis, we cluster samples based on accessible chromatin profiles to identify context-specific caQTLs. We find that caQTLs are strongly enriched for annotations of gene regulatory elements across diverse cell types and tissues and are often linked with genetic variation associated with changes in expression (eQTLs), indicating that caQTLs can mediate genetic effects on gene expression. We demonstrate sharing of causal variants for chromatin accessibility across human traits, enabling a more complete picture of the genetic mechanisms underlying complex human phenotypes. Conclusions Our work provides a proof of principle for caQTL calling from previously ungenotyped samples and represents one of the largest, most diverse caQTL resources currently available, informing mechanisms of genetic regulation of gene expression and contribution to disease.
Modification of MSCs with aHSCs-Targeting Peptide pPB for Enhanced Therapeutic Efficacy in Liver Fibrosis
Authors: Mengqin Yuan, Zhengrong Yin, Zheng Wang, Zhiyu Xiong, Ping Chen, Lichao Yao, Pingji Liu, Muhua Sun, Kan Shu, Lanjuan Li, Yingan Jiang
Journal: Biomaterials (2025)
Ultra-high gene transfection efficiency in suspension cells mediated by highly branched-linear poly(β-amino ester)s
Authors: Chenfei Wang, Tao Bo, Chen Wu, Feifei Wang, Nandi Wang, Rui Guo, Yitong Zhao, Chaolan Pan, Yuhui Zhang, Dingjin Yao, Xing Zhou, Si Zhang, Ming Zeng, Ming Li, Dezhong Zhou
Journal: Journal of Controlled Release (2025)
Bone marrow vessels are hyperpermeable to macromolecules and nanoscale medicine in a size-dependent manner
Authors: John D Martin, Kazuko Toh, Margaret R Martin, Pengwen Chen, Chenyu Wang, Kazunori Igarashi, Fotios Mpekris, Triantafyllos Stylianopoulos, Matthew D Stuber, Kazunori Kataoka, Horacio Cabral
Journal: Journal of Controlled Release (2025)

Bone marrow (BM) has roles in health and disease, so systemically administered nanocarriers (NCs) targeting or avoiding BM are desirable. While the hydrodynamic diameter of NCs can be tuned to target or avoid various organs, the size dependence of extravasation from BM vessels is unknown. To clarify the size dependence of passive transvascular transport in the BM, we performed vessel permeability measurements in murine calvaria using confocal fluorescent microscopy with fluorescently labeled dextrans, albumin, and polymeric micelles as model probes. Unexpectedly, we found the permeability of BM vessels to macromolecules decreases with increasing hydrodynamic diameter between 4 nm and 32 nm. We modeled this permeability data with mathematical models to predict an effective pore size for sinusoids of 47 nm and non-sinusoids of 37 nm, with estimated maximum pore sizes of 61 nm and 53 nm, respectively. Finally, we tested these model predictions by demonstrating that the extravasation of 70 nm polymeric micelles, which are larger than the estimated maximum pore size, is hindered relative to 30 nm polymeric micelles. These results establish design criteria for controlling NC hydrodynamic diameter towards modulating delivery to BM.
9MO: Amivantamab, lazertinib and bevacizumab in EGFR-mutant advanced NSCLC with acquired resistance to 3rd generation EGFR-TKI: Final results from the phase II ETOP AMAZE-lung trial
Authors: R.A. Soo, S. Popat, T. Dellaporta, A.J. De Langen, E. Nadal, P. Iranzo Gomez, M. Frueh, M. Pérol, G. Metro, M.A. Sala Gonzalez, M. Cucurull Salamero, F.W.F. Cerciello, A. Addeo, H. Roschitzki-Voser, B. Ruepp, A. Gasca, U. Dafni, S. Peters, R.A. Stahel
Journal: Journal of Thoracic Oncology (2025)
16P: Continued cemiplimab with addition of chemotherapy beyond progression in patients with advanced NSCLC on 1L cemiplimab monotherapy: 5-year outcomes of EMPOWER-Lung 1
Authors: M.C. Garassino, A. Baramidze, S. Kilickap, A. Sezer, M. Ozguroglu, M. Gumus, I. Bondarenko, M. Gogishvili, M. Nechaeva, M. Schenker, I. Cicin, G.F. Ho, Y. Kulyaba, K. Zyuhal, R.I. Scheusan, X. Jia, M. Kaul, J. Perez, H. Magnan, J-F. Pouliot
Journal: Journal of Thoracic Oncology (2025)
7MO: A phase II trial of tobemstomig (tobe) + platinum-based chemotherapy (chemo) vs pembrolizumab (pembro) + chemo in patients (pts) with untreated locally advanced or metastatic non-small cell lung cancer (NSCLC)
Authors: E. Nadal, A. Rittmeyer, F. De Marinis, D.H. Lee, S. Gadgeel, N. Vilariño, E. Bria, S. Arulananda, E.H. Cronenberg, V. Antic, E. Bennett, Y. Hu, K. Madden-Raja, P. Williams, H. Prizant, S. Popat
Journal: Journal of Thoracic Oncology (2025)
15P: Updated OS and final QoL and safety results of a randomised, open-label, phase III study comparing nivolumab plus ipilimumab versus carboplatin-based doublet as first-line treatment for patients with advanced NSCLC aged ≥70 years or with an ECOG PS of 2 (GFPC 08–2015 ENERGY)
Authors: H. Lena, L. Greillier, O. Bylicki, C. Cropet, I. Monnet, C. Audigier Valette, A. Vergnenegre, P. Demontrond, M. Geier, F. Guisier, R. Corre, C. Chouaid, C. Ricordel
Journal: Journal of Thoracic Oncology (2025)
5MO: First-line adagrasib (ADA) with pembrolizumab (PEMBRO) in patients (pts) with advanced/metastatic KRASG12C-mutated non-small cell lung cancer (NSCLC) and PD-L1 ≥50% from the phase II portion of KRYSTAL-7
Authors: M.C. Garassino, W.S.M.E. Theelen, P.A. Jänne, L.N. Boom, F. De Marinis, M. Dómine Gómez, E. Nadal, L. Paz-Ares, W. Gu, E. Felip, D. Hakimian, F. Kayali, J. Porter, E.S. Schaefer, L. Jimenez-Kurlander, C.M. Lane, A. Sachdeva, L.J. Eccles, A.I. Spira
Journal: Journal of Thoracic Oncology (2025)
14P: Consolidative stereotactic radiotherapy for oligo-residual non-small cell lung cancer after first-line chemoimmunotherapy: A single-arm, phase II trial
Authors: H. Chen, L. Yu, F. Liang, Y. Zhou, L. Chu, X. Chu, X. Yang, J. Zhang, Y. Pang, Z. Wang, Z. Yuan, J. Ni, Z. Zhu
Journal: Journal of Thoracic Oncology (2025)
1O: Osimertinib (osi) + datopotamab deruxtecan (Dato-DXd) in patients (pts) with EGFR-mutated (EGFRm) advanced NSCLC (aNSCLC) whose disease progressed on first-line (1L) osi: ORCHARD
Authors: X. Le, L. Hendriks, A. Morabito, L. Bonanno, I. Okamoto, J.W. Goldman, H.A. Yu, O.T. Brustugun, T.O. Halvorsen, Y.J. Kim, K. Marrone, B.C. Cho, J.W. Riess, A.J. De Langen, Z. Piotrowska, H. Ambrose, P. Smith, J.M. Lehman, P.G. Fraenkel, S.B. Goldberg
Journal: Journal of Thoracic Oncology (2025)
LBA1: First-line (1L) fulzerasib + cetuximab in KRAS G12Cm advanced NSCLC: Updated efficacy and safety from KROCUS study
Authors: M. Majem, V. Gregorc, G. Lo Russo, M. Maio, S. Salvagni, V. Gutierrez Calderon, M. Gonzalez Cao, S. Sandiego Contreras, A. Koumarianou, A. Bearz, R. Bernabe Caro, S. Viteri, M.F. Sanmamed, F. Zagouri, M.T. Moran Bueno, Y. Zhang, Y. Shan, H. Zhu, R. Rosell
Journal: Journal of Thoracic Oncology (2025)
11MO: AI-based prediction of long-term survival in NSCLC patients treated with immunotherapy: Insights from the multicentric APOLLO11 study
Authors: V. Miskovic, L. Mazzeo, C. Silvestri, A. Ferrarin, C.M. Licciardello, C.T. Saracino, R. Romanò, A. Servetto, C.M. Della Corte, G. Beshoy, M. Ganzinelli, T. Beninato, M. Occhipinti, M. Brambilla, C. Proto, C.M. Catania, L. Esposito, D. Signorelli, G. Lo Russo, A. Prelaj
Journal: Journal of Thoracic Oncology (2025)
8MO: Subcutaneous (SC) versus intravenous (IV) pembrolizumab (Pembro) plus chemotherapy (CT) in metastatic non-small cell lung cancer (mNSCLC): Phase III MK-3475A-D77 trial
Authors: E. Felip, C.I. Rojas, M. Schenker, D.M. Kowalski, I.A. Casarini, T. Csoszi, M.A.N. Sendur, J. Martins, A. Calles Blanco, C.C. Wang, X. Song, R.A. Ramırez Fallas, H. Yoshioka, S. Nair, M. Wang, X. Deng, M. Lala, R. Eiras, T. Takahashi
Journal: Journal of Thoracic Oncology (2025)
4O: Amivantamab plus lazertinib vs osimertinib in first-line (1L) EGFR-mutant (EGFRm) advanced NSCLC: Final overall survival (OS) from the phase III MARIPOSA study
Authors: J.C-H. Yang, Y.J. Kim, S-H. Lee, B. Liu, Y.V. Ostapenko, S. Lu, A. Alip, E.P. Korbenfeld, J. Dias, P. Danchaivijitr, N. Girard, E. Felip, H. Hayashi, A. Spira, B. Besse, T. Sun, M. Ennis, S. Sethi, J.M. Bauml, B.C. Cho
Journal: Journal of Thoracic Oncology (2025)
17P: Final analysis of PERLA, a global, randomized, phase II double-blind trial of dostarlimab plus chemotherapy versus pembrolizumab plus chemotherapy in metastatic nonsquamous non-small cell lung cancer
Authors: S. Peters, A.L.O. Ortega Granados, G.D.J. Pinto, C.S. Fuentes, G. Lo Russo, M. Schenker, J.S. Ahn, F. De Marinis, K.J. Locke, Z. Szijgyarto, E. Buss, N. Stjepanovic, I. Diaz-Padilla, S.M. Lim
Journal: Journal of Thoracic Oncology (2025)
18P: Telisotuzumab vedotin monotherapy in patients with previously treated c-Met protein–overexpressing nonsquamous EGFR wildtype advanced NSCLC: Updated analysis of the LUMINOSITY trial
Authors: N. Girard, D.R. Camidge, J. Bar, H. Horinouchi, J.W. Goldman, N. Daaboul, C. Liu, I. Cicin, N. Katgi, A. Zer, T-E. Ciuleanu, N. Reinmuth, D. Planchard, A.S. Mansfield, S. Baijal, N. Zhang, S. Patel, M.S. Xia, C. Ratajczak, S. Lu
Journal: Journal of Thoracic Oncology (2025)
Risk of Running—A Contemporary Look at Cardiac Arrest in Long-Distance Races
Authors: Nimesh S. Patel, Mark S. Link
Journal: JAMA (2025)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors JAMA+ AI Journals JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2025 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Cardiac Arrest During Long-Distance Running Races
Authors: Jonathan H. Kim, Austin J. Rim, James T. Miller, Mekensie Jackson, Neeya Patel, Sanchitha Rajesh, Yi-An Ko, Heather DiGregorio, George Chiampas, David McGillivray, Jay Holder, Aaron L. Baggish
Journal: JAMA (2025)

Importance More than 29 million participants completed marathons and half-marathons in the US between 2010-2023, approximately 3 times the number from 2000-2009. Contemporary long-distance race-related cardiac arrest incidence and outcomes are unknown. Objective To determine the incidence and outcomes of cardiac arrests during US marathons and half-marathons between 2010-2023 from a record of race finishers and a comprehensive review of cases from media reports, direct contact with race directors, USA Track &amp;amp;amp; Field claims, and interviews with survivors or next of kin. Design, Setting, and Participants Observational case series from the Race Associated Cardiac Event Registry; cohort data from US marathon and half-marathon runners from January 1, 2010, to December 31, 2023. Case profiles were reviewed to determine etiology and factors associated with survival. Incidence and etiology data were compared with historical reference standards (2000-2009). Exposure Recreational long-distance running (marathon and half-marathon distance). Main Outcomes Incidence proportions of sudden cardiac arrest and death. Results Among 29 311 597 race finishers, 176 cardiac arrests (127 men, 19 women, 30 sex unknown) occurred during US long-distance running races. Compared with 2000-2009, cardiac arrest incidence remained unchanged (incidence rate, 0.54 per 100 000 participants [95% CI, 0.41-0.70] vs 0.60 per 100 000 [95% CI, 0.52-0.70], respectively). However, there were significant declines in cardiac death incidence (0.20 per 100 000 [95% CI, 0.15-0.26] vs 0.39 per 100 000 [95% CI, 0.28-0.52]) and case fatality rate (34% vs 71%). Cardiac arrests remained more common among men (1.12 per 100 000 [95% CI, 0.95-1.32]) than women (0.19 per 100 000 [95% CI, 0.13-0.27]) and during the marathon (1.04 per 100 000 [95% CI, 0.82-1.32]), compared with the half-marathon (0.47 per 100 000 [95% CI, 0.38-0.57]). Among runners for which a definitive cause of cardiac arrest could be determined (n = 67/128 [52%]), coronary artery disease rather than hypertrophic cardiomyopathy was the most common etiology. Decreased cardiopulmonary resuscitation time and an initial ventricular tachyarrhythmia rhythm were associated with survival. Conclusions and Relevance Despite increased participation in US long distance running races, cardiac arrest incidence remains stable. There has been a marked decline in cardiac arrest mortality, and coronary artery disease was the most common etiology among cases with sufficient cause-related data. Effective emergency action planning with immediate access to defibrillation may explain the improvement in survival.
13P: Brain metastases and actionable genetic alterations with sacituzumab govitecan versus docetaxel in metastatic non-small cell lung cancer: Subgroups of the phase III EVOKE-01 trial
Authors: E. Felip, P. Garrido Lopez, D. Rodriguez Abreu, D.B. Daniel, T. Takahama, C. Chouaid, A. Rittmeyer, O. Juan-Vidal, M. Marcq, P. Tassone, A.B. Cortot, R. Patel, S. Mekan, N. Fernando, G. Mountzios
Journal: Journal of Thoracic Oncology (2025)
2O: SAVANNAH: Savolitinib (savo) + osimertinib (osi) in patients (pts) with EGFRm advanced NSCLC and METoverexpression (OverExp) and/or amplification (Amp) following progressive disease (PD) on osi
Authors: M-J. Ahn, T.M. Kim, L. Bonanno, S. Cheng, S-W. Kim, M. Tiseo, Q.S-C. Chu, C. Proto, A. Sacher, Y-H. Luo, C.S. Baik, L. Bazhenova, J. Cadranel, D. Bao Tuan, P. Narayanan, J.C-H. Yang, A. Gont, M. Haskins, W. Xu, F. De Marinis
Journal: Journal of Thoracic Oncology (2025)
LBA2: Taletrectinib vs crizotinib in ROS1-positive (ROS1+) non-small cell lung cancer (NSCLC): A matching-adjusted indirect comparison (MAIC)
Authors: M. Nagasaka, G. Liu, N. Pennell, M. Pérol, M. Chen, L. Bazhenova, C. Zhou
Journal: Journal of Thoracic Oncology (2025)